The latest price target for Medifast (NYSE:MED) was reported by DA Davidson on November 5, 2024. The analyst firm set a price target for $17.00 expecting MED to fall to within 12 months (a possible -6.64% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Medifast (NYSE:MED) was provided by DA Davidson, and Medifast upgraded their neutral rating.

The last upgrade for Medifast Inc happened on November 5, 2024 when DA Davidson raised their price target to $17. DA Davidson previously had an underperform for Medifast Inc.

The last downgrade for Medifast Inc happened on June 5, 2024 when DA Davidson changed their price target from $25 to $17.5 for Medifast Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest Medifast (MED) rating was a upgraded with a price target of $16.50 to $17.00. The current price Medifast (MED) is trading at is $18.21, which is out of the analyst’s predicted range.